Analyst Anshul Dhankher of LifeSci Capital maintained a Buy rating on Perspective Therapeutics (CATX – Research Report), with a price target of $21.00.
Anshul Dhankher has given his Buy rating due to a combination of factors related to Perspective Therapeutics’ promising lead program, VMT-alpha-NET. This program targets SSTR2 using the Pb-212 isotope, which is currently in Phase 1/2 trials. The interim data from these trials, shared at a recent conference, suggest potential efficacy and safety, which are encouraging signs for the company’s future prospects.
Additionally, the positive results from ITM’s Phase 3 COMPETE trial, which showed improved progression-free survival with their Lu-177-edotreotide treatment, provide a favorable backdrop for Perspective Therapeutics’ endeavors. The potential advantages of using non-carrier added Lu-177 in terms of waste management and the competitive landscape further support the Buy rating, as these factors could enhance Perspective Therapeutics’ market position and long-term growth potential.
According to TipRanks, Dhankher is an analyst with an average return of -53.3% and a 0.00% success rate.
Questions or Comments about the article? Write to editor@tipranks.com